JP2009519720A5 - - Google Patents

Download PDF

Info

Publication number
JP2009519720A5
JP2009519720A5 JP2008546030A JP2008546030A JP2009519720A5 JP 2009519720 A5 JP2009519720 A5 JP 2009519720A5 JP 2008546030 A JP2008546030 A JP 2008546030A JP 2008546030 A JP2008546030 A JP 2008546030A JP 2009519720 A5 JP2009519720 A5 JP 2009519720A5
Authority
JP
Japan
Prior art keywords
seq
dab
recombinant
disease
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2008546030A
Other languages
English (en)
Japanese (ja)
Other versions
JP5179374B2 (ja
JP2009519720A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/AU2006/001940 external-priority patent/WO2007070948A1/en
Publication of JP2009519720A publication Critical patent/JP2009519720A/ja
Publication of JP2009519720A5 publication Critical patent/JP2009519720A5/ja
Application granted granted Critical
Publication of JP5179374B2 publication Critical patent/JP5179374B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2008546030A 2005-12-20 2006-12-20 抗炎症ドメイン抗体（ｄＡｂ） Expired - Fee Related JP5179374B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
AU2005907124A AU2005907124A0 (en) 2005-12-20 Anti-inflammatory dAb
AU2005907124 2005-12-20
US81727206P 2006-06-28 2006-06-28
US60/817,272 2006-06-28
PCT/AU2006/001940 WO2007070948A1 (en) 2005-12-20 2006-12-20 Anti-inflammatory dab

Publications (3)

Publication Number Publication Date
JP2009519720A JP2009519720A (ja) 2009-05-21
JP2009519720A5 true JP2009519720A5 (enExample) 2010-06-17
JP5179374B2 JP5179374B2 (ja) 2013-04-10

Family

ID=38188157

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2008546030A Expired - Fee Related JP5179374B2 (ja) 2005-12-20 2006-12-20 抗炎症ドメイン抗体（ｄＡｂ）
JP2008546037A Pending JP2009519983A (ja) 2005-12-20 2006-12-20 部分的な新世界ザル結合領域を有するキメラ抗体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2008546037A Pending JP2009519983A (ja) 2005-12-20 2006-12-20 部分的な新世界ザル結合領域を有するキメラ抗体

Country Status (8)

Country Link
US (4) US20090286962A1 (enExample)
EP (2) EP1969009A4 (enExample)
JP (2) JP5179374B2 (enExample)
KR (1) KR20080080651A (enExample)
AU (2) AU2006326937B2 (enExample)
CA (2) CA2634083A1 (enExample)
EA (1) EA017710B1 (enExample)
WO (2) WO2007070979A1 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007019620A1 (en) * 2005-08-15 2007-02-22 Arana Therapeutics Limited Engineered antibodies with new world primate framework regions
US20090286962A1 (en) * 2005-12-20 2009-11-19 Woolven Benjamin P Chimeric antibodies with part new world primate binding regions
NZ569988A (en) * 2006-02-01 2011-09-30 Cephalon Australia Pty Ltd Domain antibody construct which binds to human TNF-alpha and contains a modified hinge region sequence and a truncated CH1 domain
US20080139790A1 (en) * 2006-12-08 2008-06-12 Jennings Philip A Chimeric antibodies
US20110319597A1 (en) * 2008-08-14 2011-12-29 Caphalon Australia Pty. Ltd. Variant domain antibodies
CN104013724A (zh) * 2014-06-20 2014-09-03 苏州法莫生物技术有限公司 一种改善睡眠的中药组合物
AU2016239949A1 (en) 2015-03-31 2017-09-07 Sorriso Pharmaceuticals, Inc. Peptide construct having a protease-cleavable linker
EP3277719B1 (en) 2015-03-31 2022-03-16 Sorriso Pharmaceuticals, Inc. Polypeptides
WO2016156468A1 (en) 2015-03-31 2016-10-06 Vhsquared Limited Polypeptides
WO2018060453A1 (en) 2016-09-30 2018-04-05 Vhsquared Limited Compositions
CN107469069A (zh) * 2017-08-18 2017-12-15 四川普莱美生物科技集团有限公司 恒河猴肺纤维化模型的造模方法、制剂、制剂的制备方法、恒河猴肺纤维化模型及其应用
CN110003330B (zh) * 2019-04-12 2022-09-09 深圳普瑞金生物药业股份有限公司 TNF-α单域抗体、核酸分子及试剂盒
CA3144566A1 (en) 2019-06-21 2020-12-24 Sorriso Pharmaceuticals, Inc. Polypeptides
US12570736B2 (en) 2019-06-21 2026-03-10 Sorriso Pharmaceuticals, Inc. Compositions
JP7692844B2 (ja) 2019-06-21 2025-06-16 ソリッソ ファーマシューティカルズ，インク． ポリペプチド

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0281604B1 (en) 1986-09-02 1993-03-31 Enzon Labs Inc. Single polypeptide chain binding molecules
GB9109645D0 (en) 1991-05-03 1991-06-26 Celltech Ltd Recombinant antibodies
US5994510A (en) 1990-12-21 1999-11-30 Celltech Therapeutics Limited Recombinant antibodies specific for TNFα
NZ243706A (en) 1991-07-25 1994-08-26 Idec Pharma Corp Recombinant monkey antibodies, pharmaceutical compositions
CA2249195A1 (en) 1996-03-18 1997-09-25 Board Of Regents, The University Of Texas System Immunoglobin-like domains with increased half lives
US6225290B1 (en) * 1996-09-19 2001-05-01 The Regents Of The University Of California Systemic gene therapy by intestinal cell transformation
US6277375B1 (en) * 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
HUP0104865A3 (en) 1999-01-15 2004-07-28 Genentech Inc Polypeptide variants with altered effector function
US7235643B2 (en) 2000-11-07 2007-06-26 Morphotek, Inc. Antibodies and methods for generating genetically altered antibodies with high affinity
GB0029407D0 (en) 2000-12-01 2001-01-17 Affitech As Product
US7754208B2 (en) * 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
GB0114856D0 (en) * 2001-06-18 2001-08-08 Medical Res Council Selection by avidity capture
US20050271663A1 (en) 2001-06-28 2005-12-08 Domantis Limited Compositions and methods for treating inflammatory disorders
US20060073141A1 (en) 2001-06-28 2006-04-06 Domantis Limited Compositions and methods for treating inflammatory disorders
AU2002368077B2 (en) * 2001-07-12 2010-03-04 Jefferson Foote Super humanized antibodies
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
ES2327830T3 (es) * 2002-03-29 2009-11-04 Schering Corporation Anticuerpos monoclonales humanos anti-interleuquina-5 y metodos y composiciones que los contienen.
US7696320B2 (en) 2004-08-24 2010-04-13 Domantis Limited Ligands that have binding specificity for VEGF and/or EGFR and methods of use therefor
US20080241166A1 (en) 2002-06-28 2008-10-02 Domantis Limited Ligands that bind a receptor
US20060034845A1 (en) 2002-11-08 2006-02-16 Karen Silence Single domain antibodies directed against tumor necrosis factor alpha and uses therefor
CA2511910A1 (en) 2002-12-27 2004-07-15 Domantis Limited Dual specific single domain antibodies specific for a ligand and for the receptor of the ligand
GB0230201D0 (en) * 2002-12-27 2003-02-05 Domantis Ltd Retargeting
GB0230203D0 (en) * 2002-12-27 2003-02-05 Domantis Ltd Fc fusion
WO2004085479A2 (en) 2003-03-26 2004-10-07 Apogenix Gmbh Treatment of viral infections
JP4889493B2 (ja) * 2003-05-14 2012-03-07 ドマンティス リミテッド ポリペプチドレパートリーから可逆的にアンフォールドするポリペプチドを回収するための方法
US20050136428A1 (en) 2003-06-27 2005-06-23 Roberto Crea Look-through mutagenesis
JP5087274B2 (ja) 2003-06-30 2012-12-05 ドマンティス リミテッド ポリペプチド
EA015363B1 (ru) * 2003-07-18 2011-06-30 Эмджен Инк. Агенты, специфически связывающие фактор роста гепатоцитов, и их применение
JP2007534305A (ja) 2003-11-07 2007-11-29 アムジェン インコーポレイテッド サル免疫グロブリン配列
WO2005052002A2 (en) 2003-11-20 2005-06-09 Massachusetts Institute Of Technology Single-domain antibodies and uses thereof
PT1718677E (pt) 2003-12-19 2012-07-18 Genentech Inc Fragmentos de anticorpo monovalentes úteis como agentes terapêuticos
CA2558811A1 (en) * 2004-03-08 2005-09-22 Zymogenetics, Inc. Dimeric fusion proteins and materials and methods for producing them
US6979473B2 (en) * 2004-03-15 2005-12-27 Boston Scientific Scimed, Inc. Method for fine bore orifice spray coating of medical devices and pre-filming atomization
WO2006014477A1 (en) 2004-07-06 2006-02-09 Bioren, Inc. HIGH AFFINITY ANTI-TNF-α ANTIBODIES AND METHOD
WO2006096653A2 (en) * 2005-03-04 2006-09-14 Biogen Idec Ma Inc. Methods of humanizing immunoglobulin variable regions through rational modification of complementarity determining residues
CA2606102C (en) 2005-04-26 2014-09-30 Medimmune, Inc. Modulation of antibody effector function by hinge domain engineering
EP1888649A2 (en) * 2005-05-09 2008-02-20 GlycArt Biotechnology AG Antigen binding molecules having modified fc regions and altered binding to fc receptors
WO2007019620A1 (en) 2005-08-15 2007-02-22 Arana Therapeutics Limited Engineered antibodies with new world primate framework regions
US20090286962A1 (en) * 2005-12-20 2009-11-19 Woolven Benjamin P Chimeric antibodies with part new world primate binding regions
NZ569988A (en) 2006-02-01 2011-09-30 Cephalon Australia Pty Ltd Domain antibody construct which binds to human TNF-alpha and contains a modified hinge region sequence and a truncated CH1 domain
JP2009525986A (ja) 2006-02-03 2009-07-16 メディミューン，エルエルシー タンパク質製剤
EP2007808A4 (en) * 2006-04-14 2010-07-21 Trubion Pharmaceuticals Inc BINDING PROTEINS HAVING AN IMMUNOGLOBULIN HINGE AND FC REGIONS WITH ALTERED EFFECTOR FUNCTIONS
US20080139790A1 (en) 2006-12-08 2008-06-12 Jennings Philip A Chimeric antibodies
CA2682605A1 (en) * 2007-04-18 2008-10-30 Zymogenetics, Inc. Single chain fc, methods of making and methods of treatment
US20110077383A1 (en) 2007-07-03 2011-03-31 Medimmune, Llc Hinge domain engineering
TW200944231A (en) 2007-11-30 2009-11-01 Glaxo Group Ltd Antigen-binding constructs
AU2009206149B2 (en) * 2008-01-16 2013-07-18 Mars, Incorporated Automated systems for feeding animals and collecting animal excrement
EP2282769A4 (en) 2008-04-29 2012-04-25 Abbott Lab DUAL VARIABLE DOMAIN IMMUNOGLOBULINS AND ITS USES
EP2669298A3 (en) 2008-05-23 2014-02-26 Ablexis, LLC Single variable immunoglobulin domain comprising VL-DH-JL

Similar Documents

Publication Publication Date Title
JP5513888B2 (ja) グルカゴン受容体抗体に関する組成物および方法
US8263076B2 (en) Anti-inflammatory dAb
JP5836130B2 (ja) ヒトｉｌ−１３に結合特異性を有する抗体分子
KR102967396B1 (ko) Gipr 항체 및 이와 glp-1의 융합 단백질, 및 그의 약학 조성물 및 적용
JP2009513712A5 (enExample)
JP2014503209A5 (enExample)
JP2008542278A5 (enExample)
JP2020506898A5 (enExample)
TW202613177A (zh) Gipr抗體及其與glp-1的融合蛋白質，以及其藥物組合物和應用
JP2005530490A5 (enExample)
JP2009165471A (ja) 糸球体腎炎および他の炎症性疾患の治療のための組成物および方法
CN108473568A (zh) 对TNF-α、IL-17A和IL-17F具有特异性的多特异性抗体分子
BRPI0707425A2 (pt) construção de anticorpo de domìnio, molécula isolada de ácido nucleico, composição farmacêutica, e, métodos para detectar tnf-alfa humano em uma amostra, e para tratar um distúrbio
JP6949012B2 (ja) Ｂ型肝炎表面抗原に対する抗体及びその使用
JP7809632B2 (ja) ＥＴＡ抗体及びＴＧＦ－β Ｔｒａｐの融合タンパク質及びその医薬組成物並びに用途
JP2020519562A (ja) 抗インターフェロンガンマ抗体およびその使用法
EP3689906B1 (en) Il-5 antibody or antigen binding fragment thereof in medical application
CN101287762A (zh) 具有新世界灵长类构架区的经改造的抗体
JP2023527918A5 (enExample)
JP2023534422A (ja) Ｂ型肝炎ウイルスの表面抗原に結合する抗体及びその使用
CN118085082A (zh) 抗猫TNF-α单克隆抗体及其应用
JP2010507362A (ja) 天然痘モノクローナル抗体
RU2800370C2 (ru) Антитело к gipr и его слитый с glp-1 белок, а также фармацевтическая композиция на его основе и его применение
HK40040729A (en) Gipr antibody and fusion protein of gipr antibody and glp-1, and pharmaceutical composition and application thereof
MX2008008029A (es) Dab antiinflamatorio